General Information of Drug (ID: DM3UE42)

Drug Name
4-arylphthalazin-1(2H)-3,4-Di-F Drug Info
Synonyms CHEMBL1934835; 4-arylphthalazin-1(2H)-3,4-Di-F; GTPL7753; BDBM50360858
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
56835134
TTD Drug ID
DM3UE42

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-830216 DMCW71N Obesity 5B81 Phase 1 [2]
AZD1979 DMQ1OX4 Obesity 5B81 Phase 1 [3]
PMID25522065-Compound-27 DMXN4KB N. A. N. A. Patented [4]
PMID25522065-Compound-29 DMBNAK9 N. A. N. A. Patented [4]
PMID25522065-Compound-34 DMZDIRQ N. A. N. A. Patented [4]
PMID25522065-Compound-39 DM5YMQH N. A. N. A. Patented [4]
PMID25522065-Compound-40 DMCIQ01 N. A. N. A. Patented [4]
PMID25522065-Compound-11 DM410Z6 N. A. N. A. Patented [4]
PMID25522065-Compound-50 DMBWA0V N. A. N. A. Patented [4]
PMID25522065-Compound-12 DMVKO9C N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanin-concentrating hormone receptor 1 (MCHR1) TTX4RTB MCHR1_HUMAN Antagonist [1]

References

1 4-arylphthalazin-1(2H)-one derivatives as potent antagonists of the melanin concentrating hormone receptor 1 (MCH-R1). Bioorg Med Chem Lett. 2012 Jan 1;22(1):427-30.
2 2011 Pipeline of Bristol-Myers Squibb.
3 Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
4 Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.